Reliance Trust Co Of Delaware buys $11,487,235 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Reliance Trust Co Of Delaware scooped up 3,608 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 190,913 shares of AbbVie Inc which is valued at $11,487,235.AbbVie Inc makes up approximately 1.05% of Reliance Trust Co Of Delaware’s portfolio.

Other Hedge Funds, Including , First United Bank Trust added ABBV to its portfolio by purchasing 3,167 company shares during the most recent quarter which is valued at $200,503. AbbVie Inc makes up approx 0.17% of First United Bank Trust’s portfolio.Canal Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 30 additional shares and now holds a total of 3,853 shares of AbbVie Inc which is valued at $243,933. AbbVie Inc makes up approx 0.23% of Canal Capital Management’s portfolio.Hills Bank Trust Co reduced its stake in ABBV by selling 25 shares or 0.59% in the most recent quarter. The Hedge Fund company now holds 4,229 shares of ABBV which is valued at $267,738. AbbVie Inc makes up approx 0.10% of Hills Bank Trust Co’s portfolio.Exxonmobil Investment Management Inc Tx reduced its stake in ABBV by selling 2,829 shares or 0.68% in the most recent quarter. The Hedge Fund company now holds 415,825 shares of ABBV which is valued at $26,167,867. AbbVie Inc makes up approx 0.55% of Exxonmobil Investment Management Inc Tx’s portfolio.

AbbVie Inc closed down -0.98 points or -1.60% at $60.17 with 56,06,474 shares getting traded on Friday. Post opening the session at $61.45, the shares hit an intraday low of $60.15 and an intraday high of $61.515 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.